Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Droperidol on Prevention of Emesis From Cannabinoid Hyperemesis Syndrome

NCT05244460 is registered in ClinicalTrials.gov with Mercy Health Ohio as lead sponsor.

NCT NCT05244460
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05244460 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Droperidol on Prevention of Emesis From Cannabinoid Hyperemesis Syndrome
Lead sponsor
Mercy Health Ohio
Phase
Phase 3
Overall status
Unknown status
Start date
December 2, 2021
Completion date
January 31, 2023
Enrollment
45 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

cannabis hyperemesis syndrome